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Objective:  Vaccination  of  infants  against  hepatitis  B  virus  (HBV)  using  hepatitis  B vaccine  is  effective  in
preventing  the  infection  during  early  childhood  and  there  is  a growing  evidence  of long-term  protection.
So  far, no  need  for a  booster  dose  has  been  identiﬁed  in  healthy  subjects;  however  further  follow-up
continues  to determine  the exact duration  of  protection.  We  evaluated  antibody  persistence  and  immune
response  to a hepatitis  B  vaccine  challenge  dose  in  children  aged  15–16  years,  previously  vaccinated  with
3-doses  of  the  same  vaccine  in infancy  (third  dose  received  before  18  months  of age).
Methods:  A single  hepatitis  B vaccine  challenge  dose  containing  10 g  hepatitis  B  surface  (HBs)  antigen
was  administered  to adolescents  aged  15–16  years.  Blood  samples  were  taken  before  and  one  month  after
the  challenge  dose  to  measure  anti-HBs  antibodies  using  a chemiluminescence  immunoassay.  Solicited
local  and  general  symptoms,  as  well  as  unsolicited  and serious  adverse  events  were  recorded  after  the
challenge  dose.
Results: 303  subjects  were  enrolled,  of whom  302  and  293  subjects  formed  the  total  vaccinated  and
according-to-protocol  cohorts,  respectively.  Pre-challenge,  65.4%  (95%  CI: 59.6–70.9)  subjects  were  sero-
protected  (anti-HBs  antibody  concentration  ≥10  mIU/mL).  One  month  post-challenge,  97.9% (95%  CI:
95.6–99.2)  were  seroprotected,  while  90.8%  (95%  CI: 86.8–93.8)  had anti-HBs  antibody  concentrations
≥100  mIU/mL.  The  post-challenge  geometric  mean  concentration  (GMC;  4134.9  [95% CI: 3114.2–5490.1])
was  150-fold  higher  than  the pre-challenge  GMC.  Overall,  96.9%  (95%  CI:  94.2–98.6)  subjects  mounted
an  anamnestic  response.  The  safety  and  reactogenicity  proﬁle  of the hepatitis  B vaccine  challenge  dose
was  consistent  with  previous  experience.
Conclusions:  Immunity  to  hepatitis  B  persists  in  15–16  year old  adolescents  following  primary  vaccination
in infancy.
Trial  registration:  http://www.clinicaltrials.gov NCT01847430.
ublis©  2016  The  Authors.  P
. Introduction
Hepatitis B infection is a serious global public health problem
nd is a major cause of chronic hepatitis, cirrhosis, and hepa-
ocellular carcinoma [1]. Approximately one-third of the world’s
opulation is estimated to have been infected by hepatitis B virus
HBV) [2]. Vaccination is the most effective way to reduce the
ncidence of hepatitis B and infection, and is particularly success-
ul when infants are targeted [2,3]. Since 1991, the World Health
Abbreviations: ATP, according to protocol; CI, conﬁdence interval; GMC, geomet-
ic  mean concentration; HBV, hepatitis B virus; WHO, World Health Organization.
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
Organization (WHO) has recommended the inclusion of hepatitis
B vaccination in national immunization programmes [4] and so far
183 countries have complied [5]. From 1995, when Germany ﬁrst
included the hepatitis B vaccine in the national routine immuniza-
tion program, [6] until 2001, routine infant vaccination has been
administered as 3 doses of monovalent recombinant hepatitis B
vaccine in the ﬁrst years of life [7].
The long-term immunogenicity induced by 3 doses of hepatitis B
vaccine is well established [3,7–10], however, studies are on-going
to determine the exact duration of protection [10–13]. Further, as
the majority of individuals mount strong anamnestic responses on
exposure to HBV many years after priming, even in the absence
of detectable circulating anti-HBs antibodies, the need for booster
dosing remains under discussion [14]. Persistent immunity and
robust immune responses to hepatitis B vaccine challenge doses
have been reported in Germany in children aged 7–8 and 12–13
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Two subjects were found positive for anti-HBc antibodies, sug-
gesting they had been in contact with the hepatitis B virus. The
medical record of those subjects revealed no evidence of past746 O. Van Der Meeren et al. /
ears, 5 and 10 years post-primary hepatitis B vaccination, respec-
ively [7]. This current study reports the long term persistence of
epatitis B vaccine in adolescents aged 15–16 years.
. Materials and methods
.1. Study design and subjects
This was a phase-IV, open-label, non-randomized study con-
ucted at 10 centres in Germany between July 2013 and February
014 (NCT01847430). This is the ﬁnal study in a series of three,
imed at measuring the long-term persistence of hepatitis B
ntibodies and the ability of the immune system to mount an
namnestic response to a challenge dose of the vaccine in differ-
nt age groups (age 7–8 years: NCT00519649 and 12–13 years:
CT00984139) [7].
The study was conducted in accordance with Good Clinical
ractice Guidelines and the Declaration of Helsinki, and the pro-
ocol and associated documents were reviewed and approved by
ocal ethics committees. Written informed consent was obtained
rom parents/guardians before enrolment.
Healthy adolescents aged 15–16 years who had received three
oses of monovalent paediatric hepatitis B vaccine (containing
0 g hepatitis B surface antigen, HBsAg) in infancy (third dose
eceived before 18 months of age), as part of routine clinical
ractice, were enrolled. Subjects who had received any additional
BV booster vaccination since primary vaccination, or presented
ith a history of hepatitis B infection, were excluded from the
tudy.
.2. Vaccine details
Subjects were vaccinated with a single dose of monova-
ent paediatric hepatitis B vaccine containing 10 g of HBsAg
EngerixTM-B Kinder; GSK Vaccines, Belgium; Lot AHBVC059A;
xpiry 28/02/2014) approximately 15 years after primary vacci-
ation. The vaccine was administered as a 0.5 mL  intramuscular
njection in the deltoid muscle using a needle 25 mm in length.
.3. Immunogenicity analyses
Blood samples were collected before and one month after
he challenge dose and were analyzed for anti-HBs antibody
oncentrations using a chemiluminescence immunoassay (CLIA).
eometric mean concentrations (GMCs) were calculated with exact
5% conﬁdence intervals (CI). Seropositivity was deﬁned as anti-
Bs antibody concentration ≥6.2 mIU/mL and seroprotection as
10 mIU/mL. Anamnestic responses to a challenge dose were also
easured; where an anamnestic response was deﬁned as ≥4-fold
ncrease in anti-HBs antibody concentration post-challenge in sub-
ects who were seropositive before receiving the challenge dose,
r post-challenge anti-HBs antibody concentration ≥10 mIU/mL in
ubjects seronegative before receiving the challenge dose.
Antibodies against hepatitis B core antigen (HBc) were deter-
ined using enzyme linked immunosorbent assay (ELISA).
.4. Safety analyses
Solicited local (pain, redness, swelling) and general symptoms
fatigue, gastrointestinal symptoms, headache and fever) occurring
uring the 4-day follow-up period, and unsolicited adverse events
AEs) occurring within 31 days of the challenge dose, were recorded
sing diary cards. The intensity of AEs was graded on a 3-point
cale where Grade 3 was deﬁned as: any symptom preventing nor-
al  daily activities; fever: axillary temperature >39 ◦C; redness or
welling: diameter >50 mm.  Serious adverse events (SAEs) were
ecorded during the entire study period.ne 34 (2016) 2745–2749
2.5. Statistical analyses
The primary endpoint of the study was the percentage of sub-
jects with anti-HBs antibody concentrations ≥100 mIU/mL one
month post-challenge. Although anti-HBs ≥10 mIU/mL is the most
relevant cut-off, validated as a correlate of clinical protection, the
primary endpoint of the study was  the percentage of subjects with
anti-HBs ≥100 mIU/mL one month after the challenge dose. We
deﬁned our primary endpoint using this more conservative cut-
off to ensure that our study would have a sufﬁcient sample size
to accurately describe the percentage that was expected to be the
lowest, i.e. anti-HBs ≥100 mIU/mL. All the objectives of the study
were descriptive.
The immunogenicity analyses were performed on the
according-to-protocol (ATP) cohort for immunogenicity, com-
prising all vaccinated subjects who  met  the eligibility criteria,
complied with protocol-deﬁned procedures and for whom data
concerning the immunogenicity endpoint measures were available
at the post-vaccination time point.
Safety analyses were performed on the total vaccinated cohort
(TVC) which included all subjects who  received the vaccination
according to the protocol.
Statistical analyses were performed using Statistical Analysis
System (SAS) versions 9.2 on SDD (SAS drug development soft-
ware).
3. Results
3.1. Demographics
303 subjects were enrolled and vaccinated, of whom 302 com-
prised the TVC; one subject was  excluded from the analysis for not
following the informed consent process.
Nine subjects were excluded from the ATP cohort for immuno-
genicity (Fig. 1). The mean age of subjects was 15.3 years (standard
deviation [SD]: 0.5 years); 53.6% subjects were male and the major-
ity (98.6%) were Caucasian/European.
3.2. ImmunogenicityFig. 1. Study design.
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Table  1
Percentage of subjects with anti-HBs antibody concentrations ≥6.2, 10 and ≥100 mIU/mL and GMCs one month after hepatitis B vaccine challenge, stratiﬁed by pre-challenge
serostatus (ATP cohort for immunogenicity).
Pre-challenge anti-HBs antibody concentrations (mIU/mL) N % subjects (95% CI) GMC (mIU/mL) (95% CI)
Post-challenge anti-HBs antibody concentrations (mIU/mL)
≥6.2 ≥10 ≥100
<6.2 85 94.1
(86.8–98.1)
92.9
(85.3–97.4)
69.4
(58.5–79.0)
353.8
(221.9–564.1)
≥6.2–<10 17 100
(80.5–100)
100
(80.5–100)
94.1
(71.3–99.9)
1598.4
(723.6–3531.1)
≥10 190 100
(98.1–100)
100
(98.1–100)
100
(98.1–100)
13,522.5
(10,626.5–17,207.7)
Overall 292 98.3
(96.0–99.4)
97.9
(95.6–99.2)
90.8
(86.8–93.8)
4134.9
(3114.2–5490.1)
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nMC: geometric mean concentration. CI: conﬁdence interval. N = number of subjec
he  speciﬁed cut-off.
epatitis B infection. They were eliminated from the ATP anal-
sis on the ground that contact with the wild virus could have
oosted their immunity, which would bias the analysis of immune
ersistence.
Immunogenicity results were available for 292 of the 293 sub-
ects comprising the ATP. While 71.2% (95% CI: 65.7–76.4) were
eropositive (anti-HBs antibodies ≥6.2 mIU/mL) before the chal-
enge dose, 65.4% (95% CI: 59.6–70.9) remained seroprotected
anti-HBs antibodies ≥10 mIU/mL). The anti-HBs antibody GMC
as 26.5 mIU/mL (95% CI: 21.4–32.8).
One month post-challenge, the percentage of seroprotected
ubjects increased to 97.9% (95% CI: 95.6–99.2) and 90.8% (95%
I: 86.8–93.8) had anti-HBs antibody concentrations ≥100 mIU/mL
Table 1). GMCs rose to 4134.9 mIU/mL (95% CI: 3114.2–5490.1), an
ncrease of over 150-fold.
An anamnestic response was observed in 96.9% (95% CI:
4.2–98.6) subjects. Nine subjects failed to mount a response; three
f these subjects still presented anti-HBs antibodies ≥100 mIU/mL,
hile six (2%) had antibody levels <10 mIU/mL before and after the
hallenge dose. Stratifying according to pre-challenge dose serosta-
us, 92.9% subjects with pre-challenge anti-HBs antibody levels
6.2 mIU/mL, all those with levels ≥6.2–<10 mIU/mL and 98.4%
ith levels ≥10 mIU/mL mounted an anamnestic response to the
epatitis B vaccine challenge (Table 2).
.3. Safety and reactogenicity
The challenge dose was generally well-tolerated. Injection site
ain (26.8% [95% CI: 21.9–32.2]) and fatigue (27.8% [95% CI:
2.8–33.2]) were the most frequently reported solicited local and
eneral symptoms, respectively; they were also the most fre-
uently reported grade 3 symptoms in their respective categories
0.3% [95% CI: 0–1.8] and 2.6% [95% CI: 1.2–5.2], respectively)
Fig. 2).
During the 31-day post vaccination follow-up period, 15.2% (95%
I: 11.4–19.8) subjects reported ≥1 unsolicited AE. Any grade 3
nsolicited AE was recorded in ﬁve subjects (1.7%) and comprised
able 2
namnestic response to the hepatitis B vaccine challenge based on pre-challenge
erostatus (ATP cohort for immunogenicity).
Pre-challenge anti-HBs antibody
concentrations (mIU/mL)
N Anamnestic response
n (%) 95% CI
<6.2 84 78 (92.9) 85.1–97.3
≥6.2–<10 17 17 (100) 80.5–100
≥10 190 187 (98.4) 95.5–99.7
Overall 291 282 (96.9) 94.2–98.6
: number of subjects with both pre- and post-vaccination results available. n (%):
umber (percentage) of responders. 95% CI: exact 95% conﬁdence interval.Fig. 2. Incidence of solicited local/general adverse events for 4-days post-challenge
(Total Vaccinated Cohort).
vertigo, streptococcal infection, lower limb fracture, migraine,
tremor and dysmenorrhoea, each in an individual subject. At least
one unsolicited AE, considered by the investigator to be vaccine-
related, was  recorded in three subjects. These symptoms were
injection site reactions (n = 4, including redness [1] and swelling
[1]), and dizziness (n = 1). Two  subjects recorded SAEs (lower limb
fracture and arthralgia), of which neither was considered to be
related to vaccination.
4. Discussion
As rates of new infection and acute disease are highest among
adults [15], it is important that long-term protection, in terms of
antibody persistence and ability to mount an anamnestic response,
is maintained. Various independent long-term follow-up trials
have assessed long-term antibody persistence and responses to
challenge doses 5 to 20 years after a 3-dose primary vaccination
course of hepatitis B vaccine in the ﬁrst year of life [7,16–20].
This current study assessed long-term antibody persistence and
immune memory in 15–16 years old adolescents.
Approximately ﬁfteen years after primary vaccination with
paediatric monovalent hepatitis B vaccine according to the local
recommendations (at age 2 months, 4 months, and 11–14 months),
65.4% subjects remained seroprotected against hepatitis B in the
current study. As expected, this is slightly lower than previous stud-
ies conducted in Germany, where seroprotection rates of 83.3% and
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8.3% were reported after 5 and 10 years of primary vaccination,
espectively [7], and reﬂects natural waning of circulating antibod-
es. These observations are in line with results from Canada [21],
nother country of low endemicity, where 85% of subjects remained
eroprotected 10 years after 3-dose hepatitis B vaccine primary
accination. Two studies from Thailand reported that around 60%
ubjects remained seroprotected 20 years after primary vaccination
18,19].
Despite declining levels of circulating anti-HBs antibodies, the
ast majority of subjects in our study were able to mount a rapid and
obust anamnestic response after a challenge dose (more than 150-
old increase in GMC) regardless of their pre-challenge serostatus.
his conﬁrms that maintaining anti-HBs antibody concentrations
10 mIU/mL may  not be essential for protection against clinically
igniﬁcant breakthrough hepatitis B infection [11]. Moreover, these
esults are in line with previous experience where 99.6% and 97.2%
f subjects aged 7–8 and 12–13 years of age, respectively, mounted
n anamnestic response after a challenge dose [7]. Similar data
re available from Germany for individuals primed with the com-
ination vaccine Infanrix hexaTM (GSK Vaccines, Belgium), which
ontains the hepatitis B vaccine component in combination with
accines against diphtheria, tetanus, acellular pertussis, polio and
aemophilus inﬂuenzae [22]. The ability to mount an anamnestic
esponse upon hepatitis B vaccine challenge remains ≥96% even
0 years after primary vaccination, demonstrating that persistence
f immune memory outlasts the presence of detectable circulating
ntibodies [19].
In our study, nine subjects failed to invoke an anamnestic
esponse, of whom six (2%) were considered unprotected before
nd after the challenge dose. This percentage is in line with the
xpected percentage of non-response following infant primary vac-
ination [18,19]. None of them presented with anti-HBc, suggesting
hat they had not developed hepatitis B infection at any point in the
ast. Three subjects failed to demonstrate an anamnestic response
hile their pre-challenge titre was >100 mIU/mL, indicative the
ersistence of protection; we hypothesize that a “saturation effect”
ould explain this outlying observation.
As the subjects included in our study received primary Hep-
titis B vaccination as part of routine clinical practice, data on
he immune response after completion of the primary vaccination
re not available. No comparisons can therefore be made between
he immune response observed immediately after primary vac-
ination with those observed at the end of long-term follow-up
eriod and poses the main limitation of this study. In particular,
e are not able to conﬁrm whether non-responders to the chal-
enge dose had responded or not to their primary immunization
ourse.
Although different studies in various settings have demon-
trated the long-term protection offered by hepatitis B vaccine,
he necessity of a booster dose still remains unanswered. However,
esults from our study, as well as from other long-term follow-
p studies support the proposal of WHO  [23,24] and the European
onsensus Group on Hepatitis B Immunity [11] that booster
accination of healthy individuals after primary hepatitis B vac-
ination in infancy is not recommended, at least for the ﬁrst 15–20
ears of life. Future studies may  ultimately further extend this
eriod.
Our results conﬁrm that paediatric doses of hepatitis B vaccine
onfer long-term protection against hepatitis B in adolescents up
o 15–16 years, and produce robust immune memory.rademark
Engerix-B Kinder and Infanrix hexa are trademarks of the GSK
roup of companies.
[ne 34 (2016) 2745–2749
Acknowledgements
The authors would like to thank all subjects and investigators
who participated in this study. The authors would also like to
acknowledge Ramandeep Singh for manuscript writing (GSK group
of companies) and Julia Donnelly (freelance on behalf of GSK group
of companies) for publication coordination.
Conﬂict of interest: OVDM and PC are employees of the GSK group
of companies and OVDM declares being in receipt of GSK stocks. UB
has no conﬂicts of interest to declare.
Funding Source: GlaxoSmithKline Biologicals SA was  the funding
source for conducting the study and performing the analysis. Glax-
oSmithKline Biologicals SA also funded all costs associated with the
development and publication of the manuscript. All authors had full
access to the data and had ﬁnal responsibility for submitting this
publication.
References
[1] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide
prevalence of chronic hepatitis B virus infection: a systematic review of data
published between 1965 and 2013. Lancet 2015 [Epub ahead of print].
[2] Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B
vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev
Vaccines 2011;10:1709–15.
[3] Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against
hepatitis B: a historical overview. Vaccine 2008;26:6266–73.
[4] World Health Organization. Expanded Programme on Immunization. Global
Advisory Group. Meeting (14th: 1991: Antalya T. Expanded Programme on
Immunization: report of the 14th Global Advisory Group, 14-18 October 1991),
Antalya, Turkey. 1992. Available at https://extranet.who.int/iris/restricted/
bitstream/10665/61561/1/WHO EPI GEN 92.1.pdf. Accessed on 04.05.15.
[5] World Health Organization. Hepatitis B fact sheet #204 - 2015. Available at
http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed on 03.11.15.
[6] Schenkel K, Radun D, Bremer V, Bocter N, Hamouda O. Viral hepatitis in
Germany: poor vaccination coverage and little knowledge about transmission
in  target groups. BMC  Public Health 2008;8:132.
[7] Behre U, Bleckmann G, Crasta PD, Leyssen M,  Messier M,  Jacquet JM, et al.
Long-term anti-HBs antibody persistence and immune memory in children
and adolescents who  received routine childhood hepatitis B vaccination. Hum
Vaccin Immunother 2012;8:813–8.
[8] Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, et al.
Long-term protection against hepatitis B after newborn vaccination: 20-year
follow-up. Infection 2010;38:395–400.
[9] Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative
long term immunogenicity of two recombinant hepatitis B vaccines and the
effect of a booster dose given after ﬁve years in a low endemicity country.
Pediatr Infect Dis J 2005;24:213–8.
10] Banatvala JE, Van Damme P. Hepatitis B vaccine - do we need boosters? J Viral
Hepat 2003;10:1–6.
11] Are booster immunisations needed for lifelong hepatitis B immunity? European
Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561–5.
12] van der Sande MA,  Waight P, Mendy M,  Rayco-Solon P, Hutt P, Fulford T, et al.
Long-term protection against carriage of hepatitis B virus after infant vaccina-
tion. J Infect Dis 2006;193:1528–35.
13] Poorolajal J, Mahmoodi M,  Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A,
Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for
booster dose: a meta-analysis. Vaccine 2010;28:623–31.
14] Van Damme  P, Van Herck K. A review of the long-term protection after hepatitis
A  and B vaccination. Travel Med  Infect Dis 2007;5:79–84.
15] Mast EE, Weinbaum CM,  Fiore AE, Alter MJ,  Bell BP, Finelli L, et al. A com-
prehensive immunization strategy to eliminate transmission of hepatitis B
virus infection in the United States: recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR
Recomm Rep 2006;55:1–33, quiz CE1-4.
16] Van Damme  P, Moiseeva A, Marichev I, Kervyn AD, Booy R, Kuriyakose S, et al.
Five  years follow-up following two or three doses of a hepatitis B vaccine in
adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis
2010;10:357.
17] Zinke M,  Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, et al.
Immune memory to hepatitis B virus in 4-9-year old children vaccinated in
infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin
2009;5:592–8.
18] Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M,  Jacquet
JM.  Persistence of antibodies and immune memory to hepatitis B vaccine 20
years after infant vaccination in Thailand. Vaccine 2010;28:730–6.
19] Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M,
Hardt K. Long-term anti-HBs antibody persistence following infant vaccination
against hepatitis B and evaluation of anamnestic response: a 20-year follow-up
study in Thailand. Hum Vaccin Immunother 2013;9:1679–84.
 Vacci
[
[
[O. Van Der Meeren et al. /
20] Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, et al. Anti-
body persistence and the effect of a booster dose given 5, 10 or 15 years after
vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine
2013;31:448–51.
21] Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G, et al. Anti-
body kinetics among 8-10 years old respondents to hepatitis B vaccination in a
low endemic country and the effect of a booster dose given 5 or 10 years later.
Vaccine 2009;27:6048–53.
[
[ne 34 (2016) 2745–2749 2749
22] Van Der Meeren O, Bleckmann G, Crasta PD. Immune memory to hepatitis B
persists in children aged 7-8 years, who were vaccinated in infancy with 4
doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine. Hum Vaccin
Immunother 2014;10:1682–7.
23] Hepatitis B vaccines: WHO  position paper - recommendations. Vaccine
2010;28:589–90.
24] Hepatitis B vaccines. WHO  Position paper. Weekly Epdemiol Rec
2004;79:255–63.
